Skip to main content
Premium Trial:

Request an Annual Quote

Roche Licenses Sangamo's ZFN Technology to Produce Cell Lines, Transgenic Animals

NEW YORK (GenomeWeb News) – Sangamo BioSciences and Sigma-Aldrich said today that Roche has licensed Sangamo’s zinc finger nuclease technology to develop cell lines and transgenic animals that have targeted modifications in specific genes.
 
Zinc finger nucleases are engineered forms of zinc finger DNA-binding proteins that can be used to help modify target genes in organisms. Sigma-Aldrich is the exclusive licensee of Sangamo’s ZFN technology for research reagents.
 
Under the agreement, Roche will receive a non-exclusive, worldwide research license to Sangamo’s ZFN technology in exchange for research maintenance fees and research event payments, and it will conduct research with both Sangamo and Sigma-Aldrich.
 
Roche also has an option to obtain an exclusive, worldwide license for the commercial use of ZFN-generated transgenic animals in the production of therapeutic and diagnostic products.
 
If it exercises this option, it will pay an additional license fee, as well as payments on clinical milestones and royalties from the sale of therapeutic and diagnostic products.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.